Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Renews License to Rubicon Technology for Breast Cancer Recurrence Test

NEW YORK (GenomeWeb) – Rubicon Genomics today announced that it has extended a clinical supply agreement providing its TransPlex whole-genome RNA amplification technology to Agendia for use in its MammaPrint 70-Gene breast cancer recurrence assay.

In early 2012, Agendia first inked the deal to use Rubicon's technology to analyze formalin-fixed, paraffin-embedded (FFPE) breast cancer samples on its Symphony suite of diagnostics, which includes MammaPrint.

Agendia received US Food and Drug Administration approval for the FFPE version of MammaPrint earlier this year. And today, Agendia announced that the test has been recommended for use in early-stage invasive breast cancer by Germany's Association of Gynecological Oncology.

The companies have now renewed their arrangement for an additional three years, which Rubicon CEO James Koziarz said in a statement was a "confirmation of the ability of our TransPlex technology to facilitate the clinical diagnostic use of FFPE samples."

"The high accuracy and … performance of Rubicon's TransPlex RNA amplification technology have contributed to our ability to obtain FDA clearance, as well as to the overall success of the MammaPrint FFPE test," Jennifer Wei, director of laboratory services at Agendia, added. "We are pleased this new contract ensures its continued availability as use of our MammaPrint FFPE assay continues to grow."

Specific terms of the new agreement were not disclosed.